{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-071082","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.077811+00:00","generated_at":"2026-06-01T05:15:47.418177+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Precision BioSciences shareholders approve increase of 630,000 shares in incentive plan","bullets":["Shareholders elected Stanley R. Frankel, M.D. and Samuel Wadsworth, Ph.D. as Class II directors for term until 2027.","Ratification of Deloitte & Touche as independent auditor for FY2024 approved with 5,162,463 votes for.","Amendment to 2019 Incentive Award Plan approved, increasing share reserve by 630,000 shares; 2,597,767 for, 836,298 against.","Adjournment proposal approved with 2,649,161 votes for, if needed to solicit additional proxies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-071082","json":"https://secwatch.observer/filing/0000950170-24-071082.json","markdown":"https://secwatch.observer/filing/0000950170-24-071082.md","text":"https://secwatch.observer/filing/0000950170-24-071082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024071082/0000950170-24-071082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024071082/dtil-20240604.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:15:47.418177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}